AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20693299 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) (50 mg/mq) combined with non-pegylated liposomal anthracycline (25 mg/mq)
Number of subjects: 56
Study 20693299 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere) (30 mg/mq) combined with non-pegylated liposomal anthracycline (25 mg/mq)
Number of subjects: 56
Study 20693299 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) and docetaxel (Taxotere) combined with non-pegylated liposomal anthracycline
Number of subjects: 56
Study 19156515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m² every 4 weeks for 6-9 cycles and weekly trastuzumab (4 mg/kg loading dose, then 2 mg/kg)
Number of subjects: 16
Study 16157451 — intervention group
Group type: COMPARATOR
Intervention: TLR4 Asp299Gly polymorphism in controls
Number of subjects: 577
Study 16157451 — intervention group
Group type: EXPERIMENTAL
Intervention: Asp/Gly and Gly/Gly genotypes
Number of subjects: 577
Study 15373006 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in a classification system for acute low back pain (1-day training session)
Number of subjects: 45
Study 11465562 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at a plasma concentration of 100 ng/ml
Number of subjects: 14
Study 11465562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11465562 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 14
Study 9794957 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 7997427 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of digoxin administered at 24‐h intervals for 7 days (study group, n = 15)
Number of subjects: 30
Study 7997427 — intervention group
Group type: COMPARATOR
Intervention: Control group with no change in the 12‐h dosage interval (n = 15)
Number of subjects: 30
Study 3375576 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 mg elemental calcium as a salt linked to an amino acid precursor
Number of subjects: 20
Study 3375576 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 mg CaC12
Number of subjects: 20
Study 3375576 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Ca as Ca gluconolactate and carbonate
Number of subjects: 20
Study 29932414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (fed condition)
Number of subjects: 0
Study 29932414 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX (fed condition)
Number of subjects: 0
Study 29932414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and AR-C124910XX (female subjects)
Number of subjects: 0
Study 29932414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and AR-C124910XX (Chinese subjects)
Number of subjects: 0
Study 29932414 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study 29683370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bao Khi Khang tablets combined with standard therapeutic protocol (Antimicrobial+Corticosteroids+Bronchodilator+Mucolytic drugs)
Number of subjects: 60
Study 29683370 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic protocol (Antimicrobial+Corticosteroids+Bronchodilator+Mucolytic drugs)
Number of subjects: 60
Study 26733764 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 17
Study 26733764 — intervention group
Group type: COMPARATOR
Intervention: CHO supplementation
Number of subjects: 17
Study 25711325 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-naïve participants in the START trial
Number of subjects: 4601
Study 25711325 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM
Number of subjects: 4601
Study 25711325 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from South America/Mexico and North America
Number of subjects: 4601
Study 25711325 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual men and women from Africa
Number of subjects: 4601
Study 25711325 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with CLS-D
Number of subjects: 4601
Study 25711325 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of ART impact on transmission risk
Number of subjects: 4601
Study 22987059 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic noninvasive analysis method based on single-channel nasal airflow signal
Number of subjects: 41
Study 22987059 — intervention group
Group type: COMPARATOR
Intervention: Gold-standard esophageal pressure scores
Number of subjects: 41
Study 20931096 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 498
Study 20931096 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 498
Study 18184240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group (received transparent anesthesia masks)
Number of subjects: 50
Study 18184240 — intervention group
Group type: COMPARATOR
Intervention: Informed group (received conventional verbal information only)
Number of subjects: 50
Study 18184240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group
Number of subjects: 50
Study 18184240 — intervention group
Group type: COMPARATOR
Intervention: Informed group
Number of subjects: 50
Study 16482200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal alprostadil (PGE1) 4 microg (1-8) and sildenafil 50 mg/day
Number of subjects: 22
Study 16482200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Trimix (20 U) 2-3 times/week and sildenafil 50 mg/day
Number of subjects: 22
Study 16482200 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile doppler studies
Number of subjects: 22
Study 14674490 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion slurry (Opalustre) for 20 seconds with a load of 200 g
Number of subjects: 16
Study 14674490 — intervention group
Group type: COMPARATOR
Intervention: Abrasive cleaning paste (Pell-ex) for 20 seconds with a load of 200 g
Number of subjects: 16
Study 9696455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 54
Study 9696455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8203510 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) infusion
Number of subjects: 29
Study 8203510 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II) infusion
Number of subjects: 29
Study 8203510 — intervention group
Group type: COMPARATOR
Intervention: Guanadrel (G) to suppress SNS activity
Number of subjects: 29
Study 2685220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 21
Study 2685220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 795437 — intervention group
Group type: EXPERIMENTAL
Intervention: Trasylol (aprotinin) treatment
Number of subjects: 4686
Study 31514507 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending Heart School
Number of subjects: 47907
Study 31217388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined noxious (CPM) and non-noxious (TENS) stimuli
Number of subjects: 44
Study 31217388 — intervention group
Group type: COMPARATOR
Intervention: Non-noxious stimuli (TENS)
Number of subjects: 44
Study 31217388 — intervention group
Group type: COMPARATOR
Intervention: Noxious stimuli (CPM)
Number of subjects: 44
Study 31217388 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 44
Study 28747329 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (OJ) consumption after 7 days of training cessation
Number of subjects: 10
Study 28747329 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (OJ) consumption during training
Number of subjects: 10
Study 23362861 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 652
Study 23362861 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 652
Study 20673244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on whether CHD was discussed
Number of subjects: 157
Study 20673244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on discussion content (pros vs cons)
Number of subjects: 157
Study 20673244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on physicians' recommendations
Number of subjects: 157
Study 20673244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on final decisions to take medication
Number of subjects: 157
Study 20673244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on final decisions to change lifestyle
Number of subjects: 157
Study 20673244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on degree of involvement in decision making
Number of subjects: 157
Study 19139673 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental booklet (The Neck Book)
Number of subjects: 187
Study 19139673 — intervention group
Group type: COMPARATOR
Intervention: Traditional booklet
Number of subjects: 187
Study 19139673 — intervention group
Group type: COMPARATOR
Intervention: No booklet
Number of subjects: 187
Study 16779656 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support behavioral intervention (up to 12 scheduled psycho-educational calls over 6 months)
Number of subjects: 177
Study 16779656 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 177
Study 15274369 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC with UFT (tegafur plus uracil)
Number of subjects: 295
Study 15274369 — intervention group
Group type: COMPARATOR
Intervention: Control (no-NAC)
Number of subjects: 295
Study 11457560 — intervention group
Group type: EXPERIMENTAL
Intervention: TAB9 (0.2 mg)
Number of subjects: 24
Study 11457560 — intervention group
Group type: EXPERIMENTAL
Intervention: TAB9 (1 mg)
Number of subjects: 24
Study 11457560 — intervention group
Group type: EXPERIMENTAL
Intervention: TAB9 (0.2 mg and 1 mg)
Number of subjects: 24
Study 11457560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9886322 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha (150 U/kg/d s.c. for 8 weeks)
Number of subjects: 87
Study 9886322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 9886322 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Number of subjects: 87
Study 7869317 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial orthopedic consultation waiting time
Number of subjects: 145
Study 7869317 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee replacement surgery waiting time
Number of subjects: 145
Study 7869317 — intervention group
Group type: EXPERIMENTAL
Intervention: Average acceptable surgical waiting time
Number of subjects: 145
Study 2405740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 50% in oxygen
Number of subjects: 165
Study 2405740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 70% in oxygen
Number of subjects: 165
Study 2405740 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 165
Study 2405740 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 165
Study 788746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 788746 — intervention group
Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 21
Study 31485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group spiritual therapy (8 sessions, 45-60 minutes each, twice a week)
Number of subjects: 50
Study 31485880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 30389671 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin prescriptions
Number of subjects: 70793
Study 30389671 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) prescriptions
Number of subjects: 70793
Study 30389671 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) prescriptions (control)
Number of subjects: 70793
Study 30389671 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet prescriptions
Number of subjects: 70793
Study 26365745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) withdrawal
Number of subjects: 40
Study 26243165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine + losartan (20 mg/day + 100 mg/day)
Number of subjects: 144
Study 26243165 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine + losartan (20 mg/day + 100 mg/day)
Number of subjects: 144
Study 23519566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 37
Study 23519566 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (control)
Number of subjects: 37
Study 21457392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) treatment (750 mg/d for 4 weeks)
Number of subjects: 32
Study 21457392 — intervention group
Group type: COMPARATOR
Intervention: No oral tranexamic acid treatment (Control)
Number of subjects: 32
Study 19042105 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine or risperidone treatment after 16 weeks
Number of subjects: 102
Study 19042105 — intervention group
Group type: COMPARATOR
Intervention: Baseline (drug naive)
Number of subjects: 102
Study 16940486 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogenic graft material (Gent‐tech) used to fill extraction sockets
Number of subjects: 39
Study 16940486 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural healing without graft)
Number of subjects: 39
Study 16540546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose D-penicillamine
Number of subjects: 134
Study 16540546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine
Number of subjects: 134
Study 14689405 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (100-200 microg/kg/min)
Number of subjects: 41
Study 14689405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (50-75 microg/kg/min)
Number of subjects: 41
Study 10522184 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IRO-group, 2 endosseous implants)
Number of subjects: 121
Study 10522184 — intervention group
Group type: COMPARATOR
Intervention: Complete denture (CD-group)
Number of subjects: 121
Study 10522184 — intervention group
Group type: COMPARATOR
Intervention: Complete denture (CD-group) with retreatment option
Number of subjects: 121
Study 10522184 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IRO-group)
Number of subjects: 121
Study 7547854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-fortified weaning cereal (200 mg Fe/kg)
Number of subjects: 0
Study 7547854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-fortified weaning cereal (500 mg Fe/kg)
Number of subjects: 0
Study 7547854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-fortified bread (65 mg Fe/kg flour)
Number of subjects: 0
Study 7547854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-fortified infant formula (12 mg Fe/l)
Number of subjects: 0
Study 7547854 — intervention group
Group type: COMPARATOR
Intervention: Non-Fe-fortified weaning cereal
Number of subjects: 0
Study 7547854 — intervention group
Group type: COMPARATOR
Intervention: Non-Fe-fortified bread
Number of subjects: 0
Study 7547854 — intervention group
Group type: COMPARATOR
Intervention: Non-Fe-fortified infant formula
Number of subjects: 0
Study 2269248 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mumol zinc, 6.4 mmol calcium and 500 mumol inositol hexaphosphate (phytic acid)
Number of subjects: 11
Study 2269248 — intervention group
Group type: COMPARATOR
Intervention: Solution not containing phytic acid (previously observed)
Number of subjects: 11
Study 2269248 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of amino acids to the solution
Number of subjects: 11
Study 35825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 0
Study 35825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31496160 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, 3 times a day)
Number of subjects: 60
Study 31496160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30800820 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based dermatology teaching module
Number of subjects: 40
Study 25760554 — intervention group
Group type: EXPERIMENTAL
Intervention: LFQS monotherapy
Number of subjects: 15
Study 25760554 — intervention group
Group type: COMPARATOR
Intervention: Combined LFQS and 30% GA peeling
Number of subjects: 15
Study 23585009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 1 mg (repeated if AF/AFL not converted after 10 min)
Number of subjects: 99
Study 23585009 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 70 mg (repeated if AF/AFL persisted after 10 min)
Number of subjects: 99
Study 23585009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 99
Study 23585009 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 99
Study 20492587 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic insoles (n=73)
Number of subjects: 228
Study 20492587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthotic insoles, n=147)
Number of subjects: 228
Study 19781418 — intervention group
Group type: COMPARATOR
Intervention: Ad hoc PCI
Number of subjects: 199
Study 19781418 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PCI (2 hours after loading)
Number of subjects: 199
Study 16769962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired ALS patients (ALSci)
Number of subjects: 10
Study 16769962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively intact ALS patients
Number of subjects: 10
Study 16769962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 16769962 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer disease patients
Number of subjects: 10
Study 15579760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (≤45 mg/d)
Number of subjects: 1199
Study 15579760 — intervention group
Group type: COMPARATOR
Intervention: Metformin (≤850 mg, three times daily)
Number of subjects: 1199
Study 11416112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 556
Study 11416112 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 556
Study 9015015 — intervention group
Group type: EXPERIMENTAL
Intervention: U technique
Number of subjects: 200
Study 9015015 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 200
Study 9015015 — intervention group
Group type: EXPERIMENTAL
Intervention: U technique and Standard technique
Number of subjects: 200
Study 8338039 — intervention group
Group type: EXPERIMENTAL
Intervention: Home trials (H1, H2, H3)
Number of subjects: 10
Study 8338039 — intervention group
Group type: COMPARATOR
Intervention: Clinical trials (C1, C2, C3)
Number of subjects: 10
Study 3486596 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 0
Study 3486596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30909715 — intervention group
Group type: EXPERIMENTAL
Intervention: Food service implementation intervention
Number of subjects: 395
Study 28444742 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 55
Study 28444742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 26030168 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults purchasing goods for others
Number of subjects: 0
Study 26030168 — intervention group
Group type: EXPERIMENTAL
Intervention: Costly giving (sharing their own candy with a puppet)
Number of subjects: 0
Study 26030168 — intervention group
Group type: COMPARATOR
Intervention: Non-costly giving (sharing the experimenter's candy with a puppet)
Number of subjects: 0
Study 26030168 — intervention group
Group type: EXPERIMENTAL
Intervention: Costly giving vs. Non-costly giving
Number of subjects: 0
Study 23174861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime snacking (192.4 ± 18.3 kcal)
Number of subjects: 11
Study 23174861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime snacking
Number of subjects: 11
Study 23174861 — intervention group
Group type: COMPARATOR
Intervention: Daytime snacking
Number of subjects: 11
Study 21763463 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy with thermal water at 38°C for 15 sessions of 30 minutes
Number of subjects: 42
Study 21763463 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 obese and 20 hypertensive patients)
Number of subjects: 42
Study 19496943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of 1 mg Ac min(‐1) with varying caloric densities (0.75/1.5/3 kcal min(‐1)) in a 200 mL meal.
Number of subjects: 18
Study 19496943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of varying tracer delivery rates (0.5/1.0/2.5 mg Ac min(‐1)).
Number of subjects: 18
Study 19496943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of increasing Ac doses (12.5/25/50/100 mg Ac in 50 mL water).
Number of subjects: 18
Study 19496943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of 50 mg Ac in 50/100/200 mL water.
Number of subjects: 18
Study 16796777 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous remission (Rc)
Number of subjects: 254
Study 16796777 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous remission (Rd)
Number of subjects: 254
Study 16796777 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous remission (Rc) among patients without cytogenetic abnormalities
Number of subjects: 254
Study 16796777 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous remission (Rd) among patients without cytogenetic abnormalities
Number of subjects: 254
Study 16796777 — intervention group
Group type: COMPARATOR
Intervention: Hypodiploidy and deletion 13
Number of subjects: 254
Study 15103751 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (single dose prior to cardiopulmonary bypass)
Number of subjects: 20
Study 15103751 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment (control group)
Number of subjects: 20